“This meeting will provide an active and dynamic environment in which a selected group of doctors and researchers of particularly invasive gliomas will be able to share their ideas, and discuss their progress and obstacles”Organizing Medical Committee
Dr. Andrés Morales
Dr. Andrés Morales is a pediatric neuro-oncologist, current clinical director of the Pediatric Oncology area, leader of the Neuro-oncology Program of the Sant Joan de Déu Children’s Hospital in Barcelona, and responsible for the SJD Pediatric Cancer Center Barcelona project, which will be one of the largest European centers of pediatric oncology. Since 2014 he is coordinator of the European research group on GC. He has been responsible for organizing the first international congress on GC in Paris (2015) and had an active participation in the second one in Washington (2017).
Trained in Lima (Cayetano Heredia University), Barcelona (Hospital Vall D’Hebron and Sant Joan de Déu), Chicago (University of Chicago) and Boston (Harvard University / Dana-Farber Cancer Institute), he has been a member of prestigious international medical institutions, he is author or co-author of numerous scientific research and has received numerous awards such as the ASCO Young Investigator Award in 2012.
Since 2017 Morales has been working on a phase Ib trial with dendritic cell immunotherapy in children with newly diagnosed DIPG. On the other hand, he has responsibilities for health management and clinical training at the Sant Joan de Déu Hospital in Barcelona.
Dra. Katherine Warren
Dr. Warren is an internationally recognized expert in pediatric Neuro-Oncology. She is a newly appointed Clinical Director of the Stop & Shop Family Pediatric Brain Tumor Program in the Department of Pediatric Oncology in Boston Children´s Hospital and previously Senior Investigator and head of the Neuro-Oncology Section in the Pediatric Oncology branch of the National Cancer Institute where she has worked for more than 25 years. Her major focus is developing new therapeutics to improve the outcome and quality of life for children with CNS tumors. Her work focuses on rational, pharmacokinetic-based drug development for children with brain tumors, and she is a leading innovator in developing new means of drug delivery. Her clinical trials have led the field in exploring new approaches for the treatment of children with these diseases. Dr. Warren has extensive experience in pharmacology, neuro-imaging, and clinical trial design and incorporates each of these into her research. She has led a number of clinical trials, including single institution, multi-institution, national consortium and international trials.
Dr. Warren currently serves as the chair of RAPNO (Response Assessment in Pediatric Neuro-Oncology), a member of the NCI Brain Malignancy Steering Committee, NCI Clinical Trials and Translational Research Advisory Committee Ad hoc Working Group on Glioblastoma, and is a steering committee member for the Pediatric Brain Tumor Consortium and the DIPG Registry. She has served on numerous national and international scientific committees and advisory boards.
Dr. Christof Kramm
Dr. Christof Kramm is Chief of Division and Full Professor of the Department of Pediatric Hematology and Oncology at the Goettingen Medical University in Germany since 2012. In addition, he is responsible for the HIT-HGG study group and the SIOPE HGG / DIPG working group.
Between 2006 and 2012 he served as vice president of the Pediatric Department of the Children’s Hospital of the University of Halle. He trained as a pediatrician at the University of Medicine of Giessen, later in neurology, oncology, hematology and palliative care, and worked as a pediatric oncologist at the University of Düsseldorf, where he remained from 1992 to 2006.
His postdoctoral research was conducted at Harvard Medical School, Massachusetts General Hospital between 1994 and 1996. His research, which has been recognized by different awards, focuses on pediatric neurooncology, especially in high-grade pediatric gliomas including DIPG.